{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:47:46Z","timestamp":1791863266998,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.reth.2026.101168","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:28:24Z","timestamp":1787563704000},"page":"101168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Advanced therapy medicinal products in Saudi Arabia: Regulation and development"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-1319","authenticated-orcid":false,"given":"Mohammed H.","family":"AlMuhanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-1155","authenticated-orcid":false,"given":"Maha","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alya","family":"Aldahash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawabi","family":"Felemban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadha","family":"Aldossary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif","family":"Alenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-1128","authenticated-orcid":false,"given":"Maram","family":"Almohaywi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2026.101168_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","article-title":"Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States","volume":"23","author":"Iglesias-Lopez","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2026.101168_bib2","article-title":"Reflection paper on classification of advanced therapy medicinal products","volume":"vol. 1","year":"2015"},{"key":"10.1016\/j.reth.2026.101168_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States","volume":"10","author":"Iglesias-L\u00f3pez","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.reth.2026.101168_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fmed.2017.00182","article-title":"Regulatory and scientific advancements in gene therapy: state-of-the-art of clinical applications and of the supporting European regulatory framework","volume":"4","author":"Carvalho","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.reth.2026.101168_bib5","series-title":"Considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.reth.2025.06.017","article-title":"Current challenges and future directions of ATMPs in regenerative medicine","volume":"30","author":"Kakroodi","year":"2025","journal-title":"Regen Ther"},{"key":"10.1016\/j.reth.2026.101168_bib7","series-title":"Human gene therapy for rare diseases [Internet]","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1623689","article-title":"Impact of regulatory measures on the approval timelines of advanced therapy medicinal products by the European Medicines Agency","volume":"12","author":"Alaburde","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.reth.2026.101168_bib9","series-title":"Approved cellular and gene therapy products","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib10","series-title":"Advanced therapy medicinal products: overview [Internet]","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib11","year":"2025"},{"key":"10.1016\/j.reth.2026.101168_bib12","series-title":"Breakthrough Medicine Program [Internet]","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib13","series-title":"Vertex's CASGEVY therapy receives approval in Saudi Arabia [Internet]","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.reth.2026.101168_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.251","article-title":"Advanced therapy medicinal products in China: regulation and development","volume":"4","author":"Lu","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.reth.2026.101168_bib17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cpt.3485","article-title":"Concordance between Pharmaceuticals and Medical Devices Agency review and Ministry of Health, Labour and Welfare decision among new drug applications in Japan","volume":"117","author":"Miyazawa","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.reth.2026.101168_bib19","article-title":"SFDA Guideline on classification of advanced therapy medicinal products","year":"2023","journal-title":"Riyadh: Saudi Food Drug Authority"},{"key":"10.1016\/j.reth.2026.101168_bib20","series-title":"Guidance for submission","year":"2022"},{"key":"10.1016\/j.reth.2026.101168_bib23","article-title":"Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs): guidance for industry. Silver Spring (MD)","year":"2020","journal-title":"FDA"},{"key":"10.1016\/j.reth.2026.101168_bib24","series-title":"Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. EMA\/CHMP\/BWP\/534898\/2008 rev. 2","year":"2022"},{"key":"10.1016\/j.reth.2026.101168_bib25","series-title":"Guidance on submission of chemistry, manufacturing, and control (CMC) information for cell-based clinical trial applications [Internet]","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib26","series-title":"Draft ANNEX for CAR T CELL","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib27","series-title":"Guide to good manufacturing practice for medicinal products","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib28","series-title":"Procedure for breakthrough medicine designation and patient access [Internet]","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib21","series-title":"Saudi Arabia regulatory system becomes third to reach WHO maturity level 4","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib22","series-title":"List of national regulatory authorities operating at maturity level 3 (ML3) and maturity level 4 (ML4) as benchmarked against the WHO Global Benchmarking Tool (GBT)","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib29","series-title":"Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. EMA\/CAT\/80183\/2014","year":"2018"},{"key":"10.1016\/j.reth.2026.101168_bib30","series-title":"Directive 2009\/120\/EC amending directive 2001\/83\/EC on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products [Internet]","year":"2009"},{"key":"10.1016\/j.reth.2026.101168_bib31","series-title":"Guidance on medical devices classification (MDS\u2013G008)","year":"2022"},{"key":"10.1016\/j.reth.2026.101168_bib32","article-title":"Registration according to verification and abridged pathways","year":"2025","journal-title":"Riyadh: Saudi Food Drug Authority"},{"key":"10.1016\/j.reth.2026.101168_bib33","year":"2024","journal-title":"Riyadh: Saudi Food Drug Authority"},{"key":"10.1016\/j.reth.2026.101168_bib34","series-title":"Guidance for priority review of product registration","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib36","series-title":"Drug quality sampling and testing programs","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib37","series-title":"ICH Q12: technical and regulatory considerations for pharmaceutical product lifecycle management","year":"2019"},{"key":"10.1016\/j.reth.2026.101168_bib38","series-title":"Post-authorisation regulatory framework for medicinal products","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib39","series-title":"Committee of Advanced Therapies holds its first meeting to develop scientific capabilities [Internet]","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib35","series-title":"As the first in the Middle East, SFDA becomes a member of the Management Committee of the International Council for Harmonisation (ICH)","year":"2025"},{"key":"10.1016\/j.reth.2026.101168_bib40","series-title":"Gene therapy products","year":"2020"},{"key":"10.1016\/j.reth.2026.101168_bib41","series-title":"SFDA joins ICH as a regulatory member","year":"2020"},{"key":"10.1016\/j.reth.2026.101168_bib43","year":"2023","journal-title":"Innovation project: point-of-care manufacturing Innovation Portfolio Report"},{"key":"10.1016\/j.reth.2026.101168_bib44","series-title":"The SFDA approves the first gene therapy for hemophilia B in the Kingdom [Internet]","year":"2025"},{"key":"10.1016\/j.reth.2026.101168_bib46","series-title":"U.S. FDA approves CSL's HEMGENIX (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B","author":"Behring","year":"2022"},{"key":"10.1016\/j.reth.2026.101168_bib45","series-title":"CASGEVY, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia in Saudi Arabia [Internet]","article-title":"Vertex announces approval of first CRISPR\/Cas9 gene-edited therapy","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib47","series-title":"SFDA approves first-of-its-kind clinical trial for a gene therapy developed in Saudi Arabia to treat acute lymphoblastic leukemia (ALL)","year":"2025"},{"key":"10.1016\/j.reth.2026.101168_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsps.2021.12.002","article-title":"Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia","volume":"30","year":"2022","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.reth.2026.101168_bib51","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.reth.2026.101168_bib52","first-page":"1458","article-title":"Prevalence and regional distribution of beta-hemoglobin variants in Saudi Arabia: insights from the National Premarital Screening Program (2011\u20132018)","volume":"60","author":"Al-Saeed","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.reth.2026.101168_bib53","first-page":"1","article-title":"Sickle cell disease in Saudi Arabia: epidemiology and management","volume":"5","author":"Al-Salem","year":"2020","journal-title":"Pediatr Hematol Oncol J"},{"key":"10.1016\/j.reth.2026.101168_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2024.2449051","article-title":"Transforming healthcare: saudi Arabia's Vision 2030 healthcare model","volume":"18","author":"Suleiman","year":"2025","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.reth.2026.101168_bib54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000531696","article-title":"A retrospective descriptive analysis of the Saudi Clinical Trials Registry from 2010 to 2021","volume":"3","author":"Aljahmi","year":"2023","journal-title":"Saudi J Health Syst Res"},{"key":"10.1016\/j.reth.2026.101168_bib56","series-title":"Regulations and requirements for conducting clinical trials on drugs","year":"2015"},{"key":"10.1016\/j.reth.2026.101168_bib59","article-title":"Guidance for orphan drug designation","year":"2023","journal-title":"Riyadh: Saudi Food Drug Authority"},{"key":"10.1016\/j.reth.2026.101168_bib55","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jsps.2021.08.013","article-title":"The characteristics of clinical studies submitted to the Saudi Food and Drug Authority from 2009 until 2020","volume":"29","author":"Aljawadi","year":"2021","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.reth.2026.101168_bib57","series-title":"REMAP-CAP: Real-Time adaptive management of patients with COVID-19 [Internet]","year":"2025"},{"key":"10.1016\/j.reth.2026.101168_bib58","series-title":"King Faisal Specialist Hospital and Research Centre (KFSHRC) [2023 research report]","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib60","series-title":"KFSHRC successfully produces the first therapeutic T-cells in the Kingdom","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib61","series-title":"CliniMACS prodigy [Internet]","author":"Biotec","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib62","series-title":"Medical Research Center KAIMRC [annual report]","author":"International","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib63","series-title":"FACT accredited institutions\u2014Countries\u2014saudi Arabia","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib64","series-title":"Saudi Arabia approves National Institute for Health Research (SNIH) to advance the clinical trials and research environment","author":"Sochacki","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib65","series-title":"Saudi NIH announces health research support opportunities","year":"2023"},{"key":"10.1016\/j.reth.2026.101168_bib48","series-title":"Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia","year":"2020"},{"key":"10.1016\/j.reth.2026.101168_bib66","series-title":"Novartis sees Saudi Arabia as a promising market for producing its cancer drugs","author":"Palmer","year":"2019"},{"key":"10.1016\/j.reth.2026.101168_bib67","series-title":"New MOU signed in Saudi to expand pharmaceutical capabilities","author":"Al Helou","year":"2022"},{"key":"10.1016\/j.reth.2026.101168_bib68","series-title":"How a Saudi start-up hopes to beat sickle cell disease with an AI-trained gene-editing biorobot","author":"Al Khunaizi","year":"2024"},{"key":"10.1016\/j.reth.2026.101168_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.773175","article-title":"Gene therapy knowledge and attitude among healthcare professionals: a cross-sectional study","volume":"9","author":"AlRasheed","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.reth.2026.101168_bib71","series-title":"SFDA joins international coalition of medicines regulatory authorities","year":"2020"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320426001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320426001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:27:34Z","timestamp":1791862054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320426001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":67,"alternative-id":["S2352320426001094"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2026.101168","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced therapy medicinal products in Saudi Arabia: Regulation and development","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2026.101168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}],"article-number":"101168"}}